Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6141951 | 0.67 | ALDH1A1 (0.37) | ALDH1A1MAPTHPGD | |
| SCHEMBL3545 | 0.67 | L3MBTL1 (0.57) | KDM4EALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL16291133 | 0.67 | L3MBTL1 (0.57) | KDM4EALDH1A1L3MBTL1MEN1KMT2A | |
| Benzene SCHEMBL29089513 | 0.64 | L3MBTL1 (0.55) | KDM4EALDH1A1L3MBTL1MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL34467257 | 0.64 | L3MBTL1 (0.55) | KDM4EALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL30398774 | 0.64 | L3MBTL1 (0.55) | KDM4EALDH1A1L3MBTL1MEN1KMT2A | |
| Benzene SCHEMBL28420098 | 0.64 | L3MBTL1 (0.55) | KDM4EALDH1A1L3MBTL1MEN1KMT2A | |
| Fluoride SCHEMBL491501 | 0.64 | L3MBTL1 (0.55) | KDM4EALDH1A1L3MBTL1MEN1KMT2A | |
| Hydrogen Sulfide SCHEMBL22588115 | 0.64 | L3MBTL1 (0.55) | KDM4EALDH1A1L3MBTL1MEN1KMT2A | |
| Bromide SCHEMBL29519314 | 0.64 | L3MBTL1 (0.55) | KDM4EALDH1A1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882022-A1 | ASPARTYL PROTEASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 1998-12-09 | — | — | EP | claimed |
| WO-1997027180-A1 | ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-07-31 | — | — | WO | claimed |
| EP-1383768-B1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2006-09-06 | — | — | EP | disclosed |
| US-7030128-B2 | Central nervous system disorders; anxiolytic agents; anticonvulsants; cognition activators; side effect reduction | MERCK SHARP & DOHME LTD. (GB) | 2006-04-18 | — | — | US | disclosed |
| US-20040092533-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-05-13 | — | — | US | disclosed |
| EP-1383768-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002076983-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-10-03 | — | — | WO | disclosed |
| WO-1999033795-A1 | PRODRUGS OF ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-07-08 | — | — | WO | disclosed |
| US-5912263-A | Taxane derivatives | PHARMACIA S.P.A. (IT) | 1999-06-15 | — | — | US | disclosed |
| EP-0882022-A1 | ASPARTYL PROTEASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997027180-A1 | ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-07-31 | — | — | WO | disclosed |
| EP-0738266-A1 | TAXANE DERIVATIVES | PHARMACIA S.p.A. (IT) | 1996-10-23 | — | — | EP | disclosed |
| EP-0738265-A1 | TAXANE DERIVATIVES | PHARMACIA S.p.A. (IT) | 1996-10-23 | — | — | EP | disclosed |
| WO-1996014308-A1 | TAXANE DERIVATIVES | PHARMACIA S.P.A. (IT) | 1996-05-17 | — | — | WO | disclosed |
| WO-1996014309-A1 | TAXANE DERIVATIVES | PHARMACIA & UPJOHN S.P.A (IT) | 1996-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092533-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | GABRA3, GABRA1, GABRA4 | KDM4E 3767/4885ALDH1A1 495/4885L3MBTL1 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.